A new spin­out wades in­to ovar­i­an ag­ing, armed with a seed round and ex­per­i­men­tal drugs from Mass Gen­er­al

There aren’t many biotechs em­pha­siz­ing women’s health, but a new spin­out is try­ing to change that.

Ovi­va Ther­a­peu­tics, a pipeline com­pa­ny of New York-based Cam­bri­an Bio­phar­ma, emerged from stealth ear­li­er this week to dive in­to the idea of ex­tend­ing women’s “healthspans,” or what it says is the part of a per­son’s life spent in gen­er­al­ly good health, with a spe­cif­ic fo­cus on ovaries. The emer­gence comes both with a seed fi­nanc­ing worth $11.5 mil­lion from Cam­bri­an, and an in-li­cens­ing agree­ment with Mass­a­chu­setts Gen­er­al Hos­pi­tal for a trio of patents.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER